Having trouble accessing articles? Reset your cache.

Constellation heading for pivotal myelofibrosis trial as ASH data lifts shares

Constellation's shares nearly doubled in value Tuesday after the company reported Phase II data showing CPI-0610 plus SOC Jakavi could improve response rates for myelofibrosis patients, along with plans to launch

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE